Keenan named president of Digirad DIS

Mar 20, 2006

Nuclear medicine vendor Digirad has selected Michael Keenan as president of its Digirad Imaging Solutions (DIS) leasing services subsidiary.

Keenan assumes his new responsibilities on March 31 this year from Digirad's CEO Mark Casner, who will relinquish the additional title, according to the Poway, CA-based firm.

By AuntMinnie.com staff writers
March 21, 2006

Related Reading

Digirad posts flat revenues, loss in 2005, February 17, 2006

Digirad partners with Ultrascan, February 9, 2006

Digirad makes management moves, January 10, 2006

Digirad prepares for triple-head rollout, December 29, 2005

Digirad shows Q3 loss, November 2, 2005

Copyright © 2006 AuntMinnie.com

Latest in Nuclear Medicine
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
Can AI improve sustainability in nuclear medicine?
April 9, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 2 -- Moving into communities
April 4, 2024
Driving the future of PET/CT.
Sponsored
Driving the future of PET/CT.
April 17, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
The rise of theranostics: Part 1 -- Gaining momentum
March 26, 2024
Related Stories
2006 01 25 15 53 01 706
Nuclear Medicine
Scintigraphy shows breast cancer response to hormone therapy sooner
2005 11 02 20 28 02 706
Nuclear Medicine
GE Healthcare
Mol
Nuclear Medicine
Rise in procedure volume drives molecular imaging's growth
Driving the future of PET/CT.
Sponsor Content
Driving the future of PET/CT.
More in Nuclear Medicine
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
SNMMI to tackle Capitol Hill
By AuntMinnie.com staff writers
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.
April 3, 2024
Us Flag
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 26, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Cannabis may influence bowel motility
By Will Morton
Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.
March 11, 2024
Cannabis
Hold off on the Egg McMuffins before GES tests, experts say
By Will Morton
Nuclear medicine technologists are being advised that not just any meal works for patients before gastric emptying scintigraphy (GES).
March 7, 2024
Stomach
Neiman HPI publishes advanced imaging prediction index
By Kate Madden Yee
The Harvey L. Neiman Health Policy Institute (HPI) has developed and released a comorbidity index designed to help predict use of advanced imaging.
January 25, 2024
2018 08 14 19 14 9213 Neiman Hip 400
IBA celebrates sale of the 100th Cyclone Kiube cyclotron
By AuntMinnie.com staff writers
Ion Beam Applications (IBA) is celebrating the sale of the 100th Cyclone Kiube cyclotron.
December 21, 2023
Iba Astro 2019
PET predicts chemotherapy responses in breast cancer patients
By Will Morton
PET/CT with gallium-68 FAPI radiotracer can predict responses to neoadjuvant chemotherapy in breast cancer patients.
November 8, 2023
Representative Ga-68 FAPI-PET/CT images of 48-year-old woman who had left invasive ductal carcinoma and who achieved pathologic complete response (pCR). (A) Baseline maximum-intensity projection (MIP) image demonstrated primary lesion (red arrowhead; SUVmax, 26.72) and Ga-68 FAPI-avid lymph node in left axilla (red arrows). (B) MIP image after two cycles of neoadjuvant chemotherapy (NAC) showed that primary lesion (red arrowhead; SUVmax, 8.87) and axillary lymph nodes (red arrow) were reduced in size and radioactivity uptake. (C and D) Representative images of lab tissue staining for FAP before NAC showed strong FAP-positive staining in stromal cells (C), which was significantly decreased on tumor bed after six cycles of NAC (D). Image courtesy of the Journal of Nuclear Medicine.
FAPI-PET bests FDG-PET in detecting gastrointestinal cancer
By Will Morton
Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer.
October 31, 2023
Nine representative patients who underwent F-18 FDG and F-18 FAPI-74 PET imaging. F-18 FAPI-74 PET outperforms F-18 FDG-PET in detecting primary tumors (patients 11, 39, 50, 58, 79, and 101; solid black arrows), local recurrences (patient 4; blue arrows), abdomen LN metastases (patients 4 and 50; green arrows), intrahepatic metastases (patient 50; red arrows), bone metastases (patient 85; arrowheads), and peritoneal metastases (patients 4, 11, 85, 97, and 101; dotted arrows). Image courtesy of the Journal of Nuclear Medicine.
PET reveals patient responses to new Alzheimer’s disease drug
By Will Morton
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab.
October 27, 2023
Tau
Pediatric PET radiotracer doses drop by a third over two decades
By Will Morton
Over the past 20 years, children have benefited from a massive reduction in PET imaging radiotracer doses without compromise in image quality.
October 20, 2023
Children
Page 1 of 436
Next Page